Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Bipolar Disorder finds that the market will be constrained over the next several years by the patent expiries and subsequent generic erosion of key antipsychotic agents such as AstraZeneca's Seroquel, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka's Abilify and Pfizer's Geodon. In 2008, sales of atypical antipsychotics exceeded $4 billion but generic competition, beginning in 2011, will cause sales of these agents to decline to just under $3 billion by 2018, according to the report. Additionally, patent expiries of branded antidepressants that include Wyeth's (now Pfizer's) Effexor XR, Eli Lilly's Cymbalta/Xeristar and Forest/Lundbeck's Lexapro/Cipralex will further constrain the market.
"Despite the overall decline in the market, we forecast that sales for bipolar disorder therapies in Europe and Japan will grow modestly from 2008 to 2018," said Decision Resources Analyst Alana Simorellis, Ph.D. "Market growth in Europe and Japan will be due in part to the continued uptake of atypical antipsychotics and an increasing drug-treated population for the indication."
The report also finds that the expanded labeling for AstraZeneca's Seroquel/Seroquel XR to include bipolar maintenance and bipolar depression as well as the potential approval of Dainippon Sumitomo's lurasidone for bipolar depression, will serve to differentiate these therapies from other atypical antipsychotics. Experts indicate that bipolar depression is difficult to treat, and there is substantial market opportunity for therapies that address this market segment.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Resources Christopher Comfort 781-296-2597 firstname.lastname@example.org Decision Resources, Inc. Elizabeth Marshall 781-296-2563 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
firstname.lastname@example.org, Elizabeth Marshall of Decision Resources, Inc.,